Johnson & Johnson Overview
Latest P/E ratio for Johnson & Johnson: 31.35 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow31.35
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for JNJ is 31.35. That is above the Healthcare sector average of 27.28. Investors often review this figure alongside Johnson & Johnson's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, JNJ currently prints 31.35 for P/E ratio, while the sector average sits near 27.28. That is roughly 14.9% above the sector mean. Large gaps often invite a closer look at Johnson & Johnson's growth, margins, and balance sheet.
A P/E ratio of 31.35 for Johnson & Johnson is not 'good' or 'bad' on its own. Compare it with the peer average (27.28) and with JNJ's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting JNJ's P/E ratio (31.35), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Johnson & Johnson's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
